KuKanich, B., Allen, P. Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy Greyhound dogs. J. vet. Pharmacol. Therap. 37, 595-597.
Fentanyl is a lipophilic mu opioid agonist with an n-octanol water partition coefficient of 860:1, pKa of 8.4 and 84.4% plasma protein binding in canine plasma (Meuldermans et al., 1982; Anonymous, 2008) . Buprenorphine is a lipophilic mu opioid partial agonist with an n-octanol-water partition coefficient of 1281:1, a pKa of 8.3 and 95-98% plasma protein binding in canine plasma (Garrett & Chandran, 1985; Roy et al., 1994) . The purpose of this study was to compare the intravenous pharmacokinetics of opioids with similar physicochemical properties in greyhound dogs.
The Institutional Animal Care and Use Committee approved the study. Six healthy 1-to 2-year-old greyhounds (three males and three females) were used weighing 26-36 kg. Treatments were administered in a nonrandomized manner (Shott, 2011) . Fentanyl (Hospira; Lake Forest, IL, USA), 10 lg/kg intravenous, was administered then buprenorphine (Reckitt Beckisser, Pharmaceuticals, Richmond, VA, USA), 20 lg/kg intravenous, with at least 2 weeks between treatments. Drugs were administered through a cephalic catheter which was rinsed with 10 mL sterile 0.9% saline after administration. Blood samples, 9 mL each, were collected from a jugular catheter prior to drug administration and 4, 8, 15, 30, and 45 min and 1, 2, 4, 6, 8 , and 12 h after drug administration. Blood was placed in lithium heparin tubes kept on ice; plasma was separated after centrifugation (3000 g for 20 min) and frozen at À70C.
Plasma drug concentrations were determined with liquid chromatography (Shimadzu Prominence, Shimadzu Scientific Instruments, Columbia, MD, USA) and mass spectrometry (API 2000, Applied Biosystems, Foster City, CA, USA). Fentanyl, fentanyl d5, buprenorphine, and buprenorphine d4 reference standards were used (Cerilliant Corporation, Round Rock, TX, USA). Plasma samples were extracted using solid-phase extraction cartridges (SPE; Varian Bond Elut C18, Varian Inc, Palo Alto, CA, USA). Plasma, 1 mL, was added to 0.1 mL of the internal standard solution (fentanyl d5, 10 ng/mL or buprenorphine d4, 25 ng/mL), and 1 mL 0.1 N sodium hydroxide and vortexed for 5 sec. The SPE were conditioned with 1 mL methanol then 1 mL deionized water, the plasma samples were added, the SPE were rinsed with 1 mL 5% methanol, and 1 mL methanol was used for drug elution. The eluent was evaporated to dryness under an air stream in a 40°C water bath and then reconstituted with 0.2 mL 50% methanol. The injection volumes were 0.05 mL; the mobile phase consisted of 0.1% formic acid and acetonitrile with separation achieved by a C18 column (Supelco Discovery, 50 mm 9 2.1 mm 9 5 lm, Sigma-Aldrich, St. Louis, MO, USA) maintained at 40°C. The qualifying and quantifying ions for fentanyl were mass to charge ratio (m/z) 337 and 188, respectively, and for fentanyl d5 were m/z 341.4 and 105, respectively. The fentanyl accuracy on replicates of 5 at 0.1, 1, and 10 ng/mL were 96, 99, and 102%, respectively, and the coefficients of variation were 9, 1, and 4% at the same concentrations. The qualifying and quantifying ions for buprenorphine were m/z 468 and 55, respectively, and for buprenorphine d4 were m/z 472 and 55, respectively. The buprenorphine accuracy on replicates of 5 at 0.5, 5, and 10 ng/mL was 101, 103, and 99%, respectively, and the coefficients of variation were 12, 4, and 5% at the same concentrations. The lower limit of quantification (LLOQ) of fentanyl and buprenorphine were 0.1 and 0.5 ng/mL, respectively.
Noncompartmental pharmacokinetic analyses were performed (WinNonlin 5.2; Pharsight Inc, Cary, NC, USA). Reported parameters include area under the curve from 0 to infinity (AUC), percent of the AUC extrapolated to infinity (AUC extrapolated ), plasma concentration extrapolated to time 0 by log linear regression of the first two time points (C0), mean residence time extrapolated to infinity (MRT), terminal half-life (T½), terminal rate constant (kz), plasma clearance (Cl), volume of distribution -area method (Vz), and volume of distribution -steady-state method (Vss). At least three time points were used for the determination of the terminal portion of the plasma profile curve. The geometric mean, minimum, median, and maximum values are reported (Table 1) .
The arithmetic mean and standard deviation plasma concentrations are presented in Fig. 1 . The doses chosen for the study (fentanyl 10 lg/kg, buprenorphine 20 lg/kg) were based on doses used clinically in canine patients. Although the doses were not identical, the primary pharmacokinetic parameters (Vz, Vss, Cl, and T½) are independent of dose in drugs that exhibit dose-independent pharmacokinetics. Previous studies have confirmed that fentanyl exhibits dose-independent pharmacokinetics from 6.4 to 640 lg/kg in dogs (Murphy et al., 1983) . Therefore, despite different doses of fentanyl and buprenorphine administered to dogs, it is not an unreasonable assumption that dose was not a prominent factor in the determination of the primary pharmacokinetic parameters in this study.
The volumes of distribution were much larger for fentanyl than buprenorphine. As pKa values are similar between the drugs, it is unlikely a major factor in the differences in the volumes of distribution. The reported octanol-water partition coefficient for buprenorphine (1281:1) is larger than the reported partition coefficient for fentanyl (860:1), which would suggest buprenorphine would be more likely to distribute and accumulate in tissues than fentanyl, leading to larger volumes of distribution for buprenorphine. However, as the partition coefficients are so large, the relatively small differences in the partition coefficients may not have a prominent effect on the volumes of distribution. The plasma protein binding of buprenorphine is much larger than fentanyl, despite both drugs being highly protein bound in canine plasma (Meuldermans et al., 1982; Garrett & Chandran, 1985; Roy et al., 1994; Anonymous, 2008) . The protein-unbound fraction of buprenorphine is expected to be only 2-5% compared to 15.6% for fentanyl, at least a threefold difference which may have an effect of restricting distribution of buprenorphine and could result in smaller volumes of distribution for buprenorphine. This was observed with significant differences in doxycycline protein binding (98% cats vs. 91% dogs) resulting in significant differences in the volumes of distribution (Vz 0.38 L cats vs. 1.01 L dogs; Riond et al., 1990) . However, the tissue binding of fentanyl and buprenorphine has not been reported in dogs and may also have an effect on the volumes of distribution.
The plasma clearance of fentanyl (38.6 mLÁmin/kg) was approximately three times greater than buprenorphine (10.3 mLÁmin/kg). The clearance of fentanyl was or exceeded the expected hepatic blood flow, suggesting that it is a high hepatic extraction ratio drug in greyhound dogs. A previous study in dogs suggested hepatic metabolism is the primary route of elimination of fentanyl in dogs (Murphy et al., 1979) .
In contrast, the plasma clearance of buprenorphine was suggestive that it has an intermediate hepatic extraction ratio. A previous study indicated 92% of buprenorphine was eliminated as glucuronide conjugates in mongrel dogs supporting it is primarily cleared by hepatic metabolism (Garrett & Chandran, 1990) . A previous study of codeine in greyounds, which is also primarily eliminated as glucuronide conjugates (KuKanich, 2010) , indicated codeine was a high hepatic extraction ratio drug, suggesting that the slower plasma clearance buprenorphine was not likely due to a deficiency in conjugation metabolism enzymes in greyhounds, but due to slower intrinsic clearance of buprenorphine.
It is unclear why the hepatic extraction ratios of fentanyl and buprenorphine appeared to differ in greyhound dogs. The larger fraction of plasma protein-unbound fentanyl may be a factor as unbound drug is available to interact with metabolizing enzymes. However, if the affinity of the drug is greater for the metabolizing enzyme than the plasma protein, a small fraction of unbound drug will not be a limiting factor. The affinity of fentanyl for its metabolizing enzymes may be greater than the affinity of buprenorphine for its metabolizing enzymes which could affect clearance. The metabolism rate for the enzymes that metabolize fentanyl may also be greater than the rate of the enzymes that metabolize buprenorphine which could also result in the greater plasma clearance of fentanyl.
The AUC extrapolated for fentanyl in two dogs was greater than 20% due to drug concentrations dropping below the LOQ of the assay. Although this extrapolation is larger than ideal, four of the dogs had less than 10% extrapolated and all of the dogs were similar in the AUC and T½. Additionally, the T½ for the dogs with >20% extrapolated AUC in this study was similar to a previous study of fentanyl in greyhounds (KuKanich, 2011) . Although the larger extrapolation potentially leads to less robust AUC and T½ estimates for two dogs administered fentanyl, the pharmacokinetic values are within previously reported ranges and within the ranges within this group of dogs. This is the first study to compare the intravenous pharmacokinetics of fentanyl and buprenorphine which have similar physicochemical properties. The pharmacokinetics were not similar, suggesting that factors other than physicochemical properties, such as plasma protein binding, may play a role in drug distribution in dogs. Further in vitro studies of intrinsic metabolism and tissue binding and distribution may provide useful data in predicting the pharmacokinetics of fentanyl and buprenorphine. Additionally, enzymatic affinity for unbound fentanyl and buprenorphine in vitro using canine enzymes may provide insight into the differences in plasma clearance.
